Mangoceuticals (MGRX) Share-based Compensation (2022 - 2026)

Mangoceuticals has disclosed Share-based Compensation across 5 years of filings, most recently posting $2.2 million for Q2 2026.

• In Q2 2026, Share-based Compensation rose 23.93% year-over-year to $2.2 million; the TTM figure through Jun 2026 stood at $2.2 million (down 51.65% YoY), while the FY2025 annual figure was $10.7 million, up 408.8% from the prior year.
• Share-based Compensation came in at $2.2 million for Q2 2026 at Mangoceuticals, roughly flat from $2.2 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $2.4 million in Q1 2024 to a low of $60000.0 in Q4 2025.
• Average Share-based Compensation over 5 years is $1.2 million, with a median of $1.4 million recorded in 2023.
• The largest YoY upside for Share-based Compensation was 1276.6% in 2025 against a maximum downside of 85.81% in 2025.
• Over 5 years, Share-based Compensation stood at $83333.0 in 2022, then jumped by 330.68% to $358901.0 in 2023, then increased by 17.79% to $422750.0 in 2024, then slumped by 85.81% to $60000.0 in 2025, then surged by 3494.44% to $2.2 million in 2026.
• Per Business Quant data, the three most recent Share-based Compensation figures were $2.2 million in Q2 2026, $2.2 million in Q1 2026, and $60000.0 in Q4 2025.